
Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials
Keywords: HIV type 1 vaccine; Recombinant fusion protein; Persistence; Efficacy; Immunogenicity; Safety; AE; adverse event; ART; antiretroviral therapy; ATP; according-to-protocol; CI; confidence interval; GMC; geometric mean concentration; HIV-1; human immunodefic